FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

You are now leaving the Roche Foundation Medicine website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your local Roche representative to obtain more information about any Roche product or service.


Click here for more information about how Roche is responding to COVID-19
Questions About Our Medicines? Visit medinfo.roche.com


Powerful insights to guide efficient, personalised treatment decisions

Like every person, every tumour is unique. Our portfolio of extensively validated comprehensive genomic profiling* services provides powerful insights to guide efficient, personalised treatment decisions – across the patient journey.1–9

A comprehensive approach to genomic profiling

The Foundation Medicine comprehensive genomic profiling approach broadly analyses the tumour genome to identify clinically relevant genomic alterations and signatures, and potentially expands patients’ treatment options. 1,2,4–6,8–14 Clinicians then receive a clear, in-depth report that supports clinical decision-making by providing insights on the patient’s genomic profile, associated targeted therapies and immunotherapies as well as relevant clinical trials.15

Our comprehensive genomic approach broadly analyses the tumour genome to identify clinically relevant alterations

*TMB reported by FoundationOne CDx and FoundationOne Heme. bTMB reported by FoundationOne Liquid CDx. MSI reported by FoundationOne CDx and FoundationOne Heme, MSI-H reported by FoundationOne Liquid CDx.
Our portfolio of comprehensive genomic profiling services enables treatment strategies to be personalised for patients in diverse clinical situations

A high-quality portfolio of services

Our portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions – across the patient journey.1─9

Overview of services

OverviewOur pioneering, FDA-approved, tissue-based, comprehensive genomic profiling service for solid tumours‡13Our next-generation, FDA-approved, liquid biopsy comprehensive genomic profiling service for solid tumours§57Our comprehensive genomic profiling service for haematological malignancies and sarcomas8,9Sample typeFFPEPeripheral whole bloodFFPE, peripheral whole blood, bone marrow aspirateGenes324>300>400Tumour Mutational Burden (TMB) / blood Tumour Mutational Burden (bTMB)Microsatellite Instability (MSI)Loss of Heterozygosity (LoH)Tumour Fraction (TF)¥¥¥¥¥¥

Guides informed, personalised treatment decisions
 
 

Supports quick, personalised treatment decisions at any time in the patient journey

For diagnostic, prognostic and predictive insights to support treatment selection
 

Combined commitment

As part of our long-standing commitment to pioneering progress in precision medicine, molecular insights leader Foundation Medicine has become a member of the Roche Group. Together Roche and Foundation Medicine are bringing comprehensive genomic profiling to cancer patients around the world, combining Roche’s expertise and commitment in oncology and Foundation Medicine’s leading technology, validation and experience in cancer profiling.16
OncologyMolecular InsightsThe right treatmentfor the right patientat the right time

*Comprehensive genomic profiling is a next-generation sequencing approach able to detect both novel and known variants, including all classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations and rearrangements) and genomic signatures (for example Tumor Mutational Burden [TMB] and blood Tumour Mutational Burden [bTMB], Microsatellite Instability [MSI] or Loss of Heterozygosity [LoH]), to provide prognostic, diagnostic and predictive insights that inform treatment decisions for individual patients across all cancer types (CGP insights can be generated either from an end-to-end, curated reporting service or through in-house testing solutions).

Approved therapies are ranked alphabetically within NCCN therapy categories (for additional information on the NCCN categories please refer to the NCCN Compendium® at www.nccn.org).

Clinical validation  demonstrated concordance with the following companion diagnostics: cobas® EGFR Mutation Test, Ventana ALK (D5F3) CDx Assay, Vysis ALK Break-Apart FISH Probe Kit, therascreen® KRAS RGQ PCR Kit, Dako HER2 FISH PharmDx® Kit, cobas® BRAF V600 Mutation Test, THxID® BRAF kit. For more information, please see the FoundationOne®CDx Technical Specifications available at: www.rochefoundationmedicine.com/f1cdxtech.

§Clinical validation demonstrated concordance with the following diagnostics: cobas® EGFR Mutation Test v2, a tumour tissue polymerase chain reaction-based clinical trial assay (CTA), and an externally validated circulating cell-free DNA-based next-generation sequencing assay. For more information please see the FoundationOne Liquid® CDx Technical Specifications available at: www.eifu.online/FMI/190070862.

¥TMB reported by FoundationOne CDx and FoundationOne Heme. bTMB reported by FoundationOne Liquid CDx. MSI reported by FoundationOne CDx and FoundationOne Heme, MSI-H reported by FoundationOne Liquid CDx.

bTMB, blood Tumour Mutational Burden; FDA, US Food and Drug Administration; FFPE, formalin-fixed paraffin-embedded; MSI, Microsatellite Instability; NCCN, National Comprehensive Cancer Network; NGS, next generation sequencing; LoH, Loss of Heterozygosity; TMB, Tumour Mutational Burden.

M-IE-00000628
References
  1. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed August 2020).
  2. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  3. FoundationOne®CDx FDA Approval, 2017. Available at: 
    https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed August 2020).
  4. Clark TA et al. J Mol Diagn 2018; 20: 686–702.
  5. [Placeholder: FoundationOne Liquid CDx Technical Specifications, 2020. Available at: TBC].
  6. Woodhouse R et al. Manuscript submitted.
  7. [Placeholder: FoundationOne Liquid CDx FDA Approval, 2020. Available at: TBC ]
  8. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed August 2020).
  9. He J et al. Blood 2016; 127: 3004–3014.
  10. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  11. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  12. Ross JS et al. Cancer 2016; 122: 2654–2662.
  13. Suh JH et al. Oncologist 2016; 21: 684–691.
  14. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  15. FoundationOne®CDx Sample Report. Available at: https://www.foundationmedicine.nl/content/dam/rfm/sample-reports/f1cdx/eu_version_-_ema_without_page_1/F1CDx%20EU%20Sample%20Report%20(Lung).pdf (Accessed August 2020).
  16. Roche Media Release, 2018. Available at: https://www.roche.com/media/releases/med-cor-2018-06-19.htm (Accessed August 2020).